Kosmas et al. [23] conducted the FOURIER (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk) trial and found that PCSK9 inhibitors did not increase the risk of diabetes when lowering LDL-C concentrations. This evidence concerns the gene PCSK9 and diabetes mellitus.